GFM
FULC icon

GF Fund Management’s Fulcrum Therapeutics FULC Stock Holding History

GF Fund Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16K Buy
1,411
+207
+17% +$1.26K ﹤0.01% 569
2026
Q1 		$9.23K Buy
1,204
+142
+13% +$1.32K ﹤0.01% 565
2025
Q4 		$12K Buy
+1,062
New +$10.8K ﹤0.01% 562

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GF Fund Management's FULC Position: Q2 2026 in Review

GF Fund Management increased its Fulcrum Therapeutics (FULC) stake by 17% in Q2 2026, buying an estimated $1.26K and bringing the position to 1,411 shares worth $5.16K. The position accounts for ﹤0.01% of the portfolio, ranked #569.

GF Fund Management first reported a position in FULC in Q4 2025 and has held it in 3 quarters since. The position peaked at $12K in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • GF Fund Management held 1,411 shares of Fulcrum Therapeutics worth $5.16K as of Q2 2026.
  • GF Fund Management bought 207 Fulcrum Therapeutics shares in Q2 2026, an estimated $1.26K.
  • Fulcrum Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #569 holding.
  • GF Fund Management first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • GF Fund Management's Fulcrum Therapeutics position peaked at $12K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.